30 May 2023, Optos, Plc, the leading retinal imaging company, today announces, it is expanding the optomap® ultra-widefield (UWF™) retinal imaging modalities available with the California FA device to further assist Eyecare Professionals in disease management and treatment planning. In addition to optomap color rg (red/green), sensory red-free, choroidal, autofluorescence (AF), fluorescein angiography (FAF) and indocyanine green angiography (ICGA) modalities, the company is pleased to announce the first ultra-widefield color rgb (red/green/blue) image. This new image modality is captured simultaneous to the optomap color rg image. Thus, a single capture delivers two amazing color ultra-widefield images.
Rob Kennedy, CEO of Optos, said, “We are pleased to bring another image modality to our California FA device. The optimized color palette used in the new optomap ultra-widefield color rgb image was created in close collaboration with eyecare professionals. The new image modality, in addition to our clinically validated optomap color rg images, provides additional retinal visualization to our customers as they manage their patient’s treatment and ongoing care”.
Initial feedback from customers who saw the new image at the American Society of Cataract and Refractive Surgery (ASCRS) meeting was very positive.
David M. Brown, MD from Retina Consultants of Texas, the lead author for a poster presented at The Association for Research in Vision and Ophthalmology (ARVO) commented about the newest image modality, “Optos imaging has revolutionized retina and is indispensable in the management of retinal vascular diseases. The optomap color rgb is particularly impressive in its ability to discern holes in peripheral lattice degeneration and retinoschisis which leads to immediate improvement to patient care. It is an exponential advancement in retinal imaging that will rapidly become the standard of care in our mutual fight against blindness”.
Prof Paulo E. Stanga, Director & Vitreoretinal Surgeon at The Retina Clinic, London added, “The newest ultra-widefield modality in California allows us to see a natural colour single capture ultra-widefield image. It has been exciting, in my day-to-day clinic, to see the improved detail of drusen in intermediate AMD patients, better characterise them, and track their progression. We can easily visualize the extent and severity of a macular epiretinal membrane and better grade diabetic retinopathy. I cannot envision my retina clinics without the assistance of Optos technology”.
“Including a blue wavelength to an optomap ultra-widefield image is most helpful for capturing a record of that patient’s fundus biomicroscopy, added Steve M. Bloom, MD, retina specialist at Bennett & Bloom Eye Center, Kentucky. “Looking at these color rgb ultra-widefield images makes me smile, and realize that in both health and disease, the retina remains a work of art.”
About Optos
Optos, a subsidiary of Nikon Corporation, is the leading retinal imaging company. Its core technology, ultra-widefield (UWF™) high-resolution digital images (optomap) capture approximately 82% and 200◦ of the retina, something no other device can do in a single image.
Optos has also developed integrated ultra-widefield retinal imaging with image-guided Optical Coherence Tomography (OCT). Optos devices facilitate the early detection, management, and effective treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy, and age-related macular degeneration.
More than 2,000 published clinical studies show the long-term value of optomap imaging with OCT in diagnosis, treatment planning, and patient engagement.
For more information about Optos, please visit our website. All optomap image modalities may be seen on optomap Recognizing Pathology.
Inquiries:
Leslie Amodei, Executive Vice President, Global Marketing, Optos
Teresa Panas, Principal, TGP Communications, LLC
